Navigation Links
Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Date:4/9/2008

SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in two ongoing Phase 2 clinical trials for the treatment of hormone-refractory prostate cancer and metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-lo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
4. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
8. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... from FDA, Favorable Scientific Advice from EMEA and Phase 3 ... Cell ... Dr. Giuseppe Giaccone,Chief of the Medical Oncology Branch at ... double-blind,placebo-controlled Phase 2 trial with talactoferrin alfa in non-small cell,lung ...
... Bionomics Limited (ASX:,BNO) today announced the initiation of treatment ... its anti-cancer drug, BNC105., The BNC105 Phase I ... will be treated with BNC105 on days 1 and ... trial will be conducted at clinical,sites within the Cancer ...
Cached Medicine Technology:Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 2Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 3Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 4Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 5Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 6Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 7Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 2Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 3
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... Bethesda, MD (April 23, 2014) The American ... announce the 2014 AGA Research Scholars. The AGA ... young investigators to develop independent and productive research ... Research Scholar Awards fund an additional year allowing ... is committed to supporting junior faculty who are ...
(Date:4/23/2014)... 2014 Five for-profit and non-profit organizations in ... in Proof of Concept grants to accelerate maturation ... products, the Life Sciences Discovery Fund (LSDF) announced ... Program grant to the Washington Biotechnology & Biomedical ... to train the next generation of entrepreneurs and ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... school sport in the United States with 1 million ... the Center for Injury Research and Policy at Nationwide ... the occurrence and distribution patterns of basketball-related injuries treated ... setting among adolescents and teens. , The study, published ... examined data relating to adolescents 13-19 years of age ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3
... Clements International develops unique suite of insurance solutions for the medical ... and India, Clements has designed liability, accident and trip cancellation insurance ... ... Washington, DC (PRWEB) September 11, 2008 -- Clements International develops ...
... PITTSBURGH, Sept. 10 , Who: ... appreciation to guests for supporting the,chain,s smoke-free policy with a free ... September 11, 5 p.m. to 8 p.m. (with purchase of a ... Eat,n Park -- the state,s leading family dining chain -- is,giving ...
... services, today announced that it was selected to ... support services for independent physicians affiliated with El ... solutions designed for smaller medical practices. ITelagen, which ... is providing professional help desk services and support ...
... Australia, Sept. 10 Ellex Medical Lasers,Limited (ASX: ... global,reach with the establishment of a direct sales ... be formally launched at the European Society of ... September 2008, Ellex,Deutschland GmbH will focus initially on ...
... Pay for ... Medical Bills, 30% of Consumers Receiving Care for a Critical Illness Have Not Recovered ... Financially, ... pay for major medical recovery expenses and both sexes,largely agree that a critical illness would ...
... WEST PALM BEACH, Fla., Sept 10 If ... a bag of chips or a quart of ... with emotional eating, which can,now be helped with ... ), the first vegan, gluten-free vitamin with ...
Cached Medicine News:Health News:Clements International Develops Insurance for Medical Tourism Industry 2Health News:El Camino Hospital Selects ITelagen for Multimillion-Dollar Electronic Medical Records (EMR) Initiative; Program Will Offer More Than 100 Participating Physicians State-of-the-Art Service and Support 2Health News:El Camino Hospital Selects ITelagen for Multimillion-Dollar Electronic Medical Records (EMR) Initiative; Program Will Offer More Than 100 Participating Physicians State-of-the-Art Service and Support 3Health News:Ellex Commences Direct Sales in Germany 2Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 2Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 3Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 4Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 5Health News:Guardian Survey: Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 6Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 2Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: